$94.96
-2.77 (-2.83%)
Open$98.18
Previous Close$97.73
Day High$98.29
Day Low$94.52
52W High$115.52
52W Low$14.89
Volume—
Avg Volume739.9K
Market Cap6.29B
P/E Ratio—
EPS$-2.46
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-78.2% upside
Current
$94.96
$94.96
Target
$20.70
$20.70
$16.39
$20.70 avg
$27.30
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 372.50M | 351.85M | 301.99M |
| Net Income | -104,674,461 | -84,234,881 | -79,583,487 |
| Profit Margin | -28.1% | -23.9% | -26.4% |
| EBITDA | -120,858,001 | -107,157,018 | -93,330,324 |
| Free Cash Flow | -75,919,374 | -55,757,162 | -73,499,960 |
| Rev Growth | -6.8% | +18.4% | +6.2% |
| Debt/Equity | 0.83 | 0.74 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |